Valneva SE INRLF
2.49 USD 0.00 (+0.00%)
At closeNov 4, 2026, 4:00 PM EST
3.00 Day range 3.00
2.43 52-week range 5.90
- YTD
- -40.71%
- 1 year
- -45.87%
News
seekingalpha.com Valneva SE (VALN) Q1 2026 Earnings Call Transcript Valneva SE (VALN) Q1 2026 Earnings Call Transcript
globenewswire.com VALNEVA: Declaration of shares and voting rights - Status as of April 30, 2026 taking into account interim information as at May 5, 2026 Registered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon Regulated market of Euronext Paris - Compartment B
globenewswire.com Declaration of shares and voting rights of Valneva SE – March 2026 VALNEVA Declaration of shares and voting rights March 31, 2026 __________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot…
wsj.com An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.
benzinga.com Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive The Phase 3 VALOR trial results showed that fewer Lyme disease cases were accrued than anticipated, and the primary endpoint was not met in the first analysis.
wsj.com Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial Pharmaceutical giant Pfizer and French vaccine maker Valneva reported positive topline results from their phase three study of a vaccine candidate for Lyme disease.
reuters.com Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial U.S. drugmaker Pfizer and France's Valneva said on Monday their experimental Lyme disease vaccine showed more than 70% efficacy in a late-stage trial.
businesswire.com Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 VALOR “Vaccine Against Lyme for…
seekingalpha.com Valneva SE (VALN) Q4 2025 Earnings Call Transcript Valneva SE (VALN) Q4 2025 Earnings Call Transcript
globenewswire.com VALNEVA Declaration of shares and voting rights: February 28, 2026 VALNEVA Declaration of shares and voting rights February 28, 2026 __________________________________________________________________________________________ Company name: VALNEVARegistered office:…
globenewswire.com VALNEVA Declaration of shares and voting rights: January 31, 2026 Registered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon.
reuters.com Valneva withdraws application for standard US approval of its chikungunya shot French drugmaker Valneva said on Monday it has voluntarily withdrawn its application seeking standard approval of its chikungunya vaccine in the United States after the FDA suspended the shot's…
globenewswire.com Valneva SE - Declaration of voting rights - December 2025 Registered office: Îlot Saint Joseph Bureaux Convergence – 12T Quai Perrache – 69002 Lyon
globenewswire.com Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement Saint-Herblain (France), Pune, (India), December 31, 2025 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company…
globenewswire.com VALNEVA Declaration of shares and voting rights: November 30, 2025 Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France).
benzinga.com Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings Valneva SE (NASDAQ: VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15.
wsj.com Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study Valneva said that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups in the trial.
seekingalpha.com Valneva SE (VALN) Q3 2025 Earnings Call Transcript Valneva SE ( VALN ) Q3 2025 Earnings Call November 20, 2025 9:00 AM EST Company Participants Joshua Drumm - Vice President of Investor Relations Thomas Lingelbach - President, CEO & Director Peter…
globenewswire.com VALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Valneva SE on Behalf of Valneva Stockholders and Encourages Investors to Contact the Firm Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Valneva (VALN) To Contact Him Directly To Discuss Their Options If you purchased or acquired…
benzinga.com Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday U.S. stocks were mixed, with the Dow Jones index falling more than 200 points on Monday.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday